Skip to main content

Table 3 Summary of preclinical reports based on manufacture of next generations CAR T cells using genome editing technologies

From: Hurdles to breakthrough in CAR T cell therapy of solid tumors

Cancer Study type Target locus Tool CAR Reference
Liver cancer In vitro TGFβRII CRISPR/Cas9 Mesothelin [179]
Ovarian cancer In vivo     
Leukemia In vivo TRAC CRISPR/Cas9 CD19 [187]
Leukemia In vitro TRAC TALEN CD19 [188, 189]
  In vivo     
Myeloma In vitro CD20 TALEN BCMA [190]
  In vivo     
Leukemia In vitro GM-CSF CRISPR/Cas9 CD19 [178]
  In vivo     
Leukemia In vitro TRAC CRISPR/Cas9 CD7 [191]
  In vivo     
Lymphoma In vitro TRAC TALEN CD22 [192]
  In vivo PD-1    
Leukemia In vitro TRAC CRISPR/Cas9 CD22 [193]
   PD-1    
Leukemia In vitro TRAC TALEN CD3 [194]
  In vivo     
Leukemia In vitro TRAC TALEN CD20 [195]
   PD-1    
Leukemia In vivo LAG-3 CRISPR/Cas9 CD19 [135]
Prostate cancer In vivo TRAC CRISPR/Cas9 PSCA [134]
   B2M    
   PD1    
Lymphoma In vitro GM-CSF TALEN CD22 [196]
Glioma In vitro PD-1 CRISPR/Cas9 EGFRvIII [197]
Glioma In vitro PD-1 CRISPR/Cas9 CD133 [198]
  In vivo     
Leukemia In vitro TRAC ZFN CD19 [199]
Glioma In vitro DGK CRISPR/Cas9 EGFRvIII [200]
  In vivo     
Prostate cancer In vivo TRAC CRISPR/Cas9 PSCA [134]
   B2M    
   PD1    
Leukemia In vitro TRAC CRISPR/Cas9 BCMA [174]
     CD10  
  1. Acute lymphoblastic leukemia (ALL), B-cell lymphoma (BCL), Epidermal growth factor receptor variant III (EGFR vIII), Prostate stem cell antigen (PSCA), B-cell maturation antigen (BCMA), Diacylglycerol kinase (DGK), Transforming growth factor beta receptor II (TGFβRII), T cell receptor alpha constant (TRAC), Beta-2-microglobulin (B2M), Programmed cell death protein 1 (PDCD1 or PD1), Lymphocyte-activation gene 3 (LAG-3), Granulocyte–macrophage colony-stimulating factor (GM-CSF)